Equities

Ellen AB

Ellen AB

Actions
Health CarePharmaceuticals & Biotechnology
  • Price (SEK)0.535
  • Today's Change-0.005 / -0.93%
  • Shares traded22.51k
  • 1 Year change-20.15%
  • Beta0.3686
Data delayed at least 15 minutes, as of Sep 26 2016 16:29 BST.
More ▼

Profile data is unavailable for this security.

About the company

Ellen AB is a Sweden-based biotechnology company that produces probiotic sanitary protection products for women. The Company’s main product, Ellen tampon, contains patented natural lacto acid bacteria, Lacto Naturel (LN), and is used for maintaining the vaginal health. The Ellen tampon is made of natural fibers treated with the substance LN, which consists of human lactic acid bacteria, a natural part of healthy women's defense against infections. Ellen AB distributes its products in 37 countries, including Scandinavian countries, France, Germany, Czech Republic, Spain, Portugal, Poland and Belgium, among others. As of December 31, 2011, the Company had two subsidiaries, including the wholly owned Ellen Australia pty LTD and the 70%-owned Ellen Asia LTD. As of December 31, 2011, its largest shareholder was Banque Ohman S.A. (18.73%). On July 3, 2013, it launched an online store, www.ellen.se, where customers can search for products' information and shop online.

  • Revenue in SEK (TTM)18.86m
  • Net income in SEK-5.34m
  • Incorporated--
  • Employees6.00
  • Location
    Ellen ABSvardvagen 25 B, 1trDANDERYD 182 33SwedenSWE
  • Phone+46 84121000Fax+46 84121020
  • Websitehttp://www.ellenab.se
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Kerdos Group SA18.05m-208.67m7.03m48.007.03m48.00
Izmir Firca Sanayi ve Ticaret AS19.99m468.07k14.74m82.0014.74m82.00
Ellen AB18.86m-5.34m37.09m6.0037.09m6.00
Photocat A/S5.96m-8.47m55.41m--55.41m--
Data as of Sep 26 2016. Currency figures normalised to Ellen AB's reporting currency: Swedish Krona SEK
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.